The sleep supplement market has grown to billions, with almost no regulation compared to pharmaceuticals, and the gap between what is claimed on packaging and what research actually supports has grown with it. Here’s what’s really going on behind some of the most common tactics.
"Clinically proven" usually doesn't mean anything close to what it implies
A product that calls itself clinically proven does not have to mean that the finished product, in its actual dose and formulation, has ever been tested in a real study. Often, the claim relies on a single ingredient in the formula appearing in some unrelated study, at a completely different dose, sometimes in a different form, sometimes in animals instead of humans. The finished bottle on the shelf was never what was tested. This is legal because "clinically proven" is not a regulated term with a fixed definition, and the industry has learned how far this ambiguity can stretch.
Proprietary blends exist to hide underdosing
A proprietary blend lists the ingredients of a formula without disclosing how much of each is included, only the combined total weight. This is not a protected manufacturing secret, but a legal way to put a hero ingredient on the front of the label, at a dose too small to match the research behind it, without the customer ever being able to verify the discrepancy. Independent tests of best-selling sleep and NAD+ products have repeatedly found that a significant proportion deliver only a fraction of the active ingredient suggested by the label, sometimes barely a trace.
High-dose melatonin is not more effective, it's cheaper to market
Melatonin doses on the market have increased over the years; some products are now sold with ten to twenty times the doses with which melatonin's efficacy was originally proven. Clinical evidence supports doses in the range of 0.5 to 3 milligrams for most adults, and higher doses have not been shown to be significantly more effective. They are just easier to market as stronger, more serious solutions. Some research even suggests that high-dose melatonin can cause grogginess the next day and disrupt the body's natural melatonin production over time, the opposite of the intended effect.
Fear is a marketing strategy, not a diagnosis
A significant portion of sleep and longevity marketing operates with artificial urgency, framing entirely normal biological processes as emergencies that demand immediate purchase. The tactic works because it borrows real, reputable research—actual findings on NAD+ decline, actual findings on sleep architecture—and repackages them with alarmist language designed to bypass careful evaluation. The research itself is often real. The framework around it is built to make a rational purchasing decision feel like an emergency decision.
"Natural" and "science-backed" are not interchangeable, and brands know it
A product can consist entirely of natural ingredients and still not be supported by any human research, and a product can call itself science-backed while citing studies conducted on a different compound, a different dose, or a completely different target group than the one buying the bottle. These two terms are used almost synonymously in marketing precisely because most customers assume they mean the same level of evidence. They don't, and the industry has little incentive to explain the difference.
Purity tests are voluntary, and most brands skip them
Third-party testing, i.e., independent laboratory verification of whether a product actually contains what the label claims, is not a regulatory requirement for supplements in most markets. It is completely voluntary, and a brand that skips it saves money and incurs no legal consequences for a label that does not match the bottle's contents. A testing claim on the packaging means little without the specific certificate of analysis from a named laboratory for the sold batch, which a customer can view.
What this actually means for purchasing decisions
None of this means that every sleep product on the market is dishonest, or that natural ingredients and confident marketing automatically indicate a problem. It means that the burden of verification currently lies entirely with the customer, in an industry that is practically not obligated to make this verification easy. Paying attention to a disclosed dose instead of a proprietary blend, to a named testing laboratory instead of a vague claim, and to a study reference that actually matches the product sold instead of a loosely related investigation: that is the difference between an assessment based on real evidence and an assessment based on how convincingly something was marketed.